![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NEUROSCIENCE THERAPY CORP. REVEALS ECONOMIC IMPACT OF PAIN
NEUROSCIENCE THERAPY CORP. REVEALS ECONOMIC IMPACT OF PAIN
May 2, 2006
Neuroscience Therapy Corp. reports economic statistics related to pain and the burden it puts on society. The Company believes its leading product P-Stim will help to alleviate this burden. Chronic pain is the most costly health problem in the U.S. today, according to the NIH and UAB Health Systems. It is estimated that 98 million people in the U.S. suffer from just the four most common types of chronic pain: arthritis pain, migraine pain, low back pain and cancer pain.
CNW Group
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct